Evaluation of Common Coagulation Tests in Type 2 Diabetic Patients and Association with Diabetic Pre-cardiovascular Complications, Gezira State–Sudan, 2020-2021
Asian Hematology Research Journal,
Background and Objectives: Diabetes has an epidemic character because of the huge growth within side the wide variety of human affected in latest years. If laboratory findings display abnormalities connected to an improved threat of thrombosis, diabetes, specifically type 2, can present hypercoagulability symptoms. The aim of this study to evaluate the common coagulation parameters PT, aPTT, and D-dimer in patients suffering with diabetes type 2 and to associate these parameters with the thrombotic complication in those patients.
Methods: This was a case control study performed on 70 patients with diabetic type 2 from different ages (Their ages ranging from 20 -72 years with an average age of 56.2 years) and different gender (41.4% were males and 58.6% were females) attending the Diabetic Clinic of the Aldaraja Health Center, compared with 50 apparently healthy individual as a control group were enrolled in study and that in Wad Madeni, Gezira State, central of the Sudan in the period between June 2020 to January 2021, Blood were collected from each enrolled subject and the levels of PT, aPTT and D-dimer were measured.
Results: This study showed lower levels of PT and aPTT (patients 13.3 seconds/ control 14.3 seconds and patients 34.3 seconds/ control 36.6 seconds) respectively with highly significance difference (P. value = 0.001) respectively when compared with control group, while showed higher level of D-dimer (patients 585.3 ng/ml/ control 178.58 ng/ml) with highly significant difference (P. value = 0.000) when compared with control group. In diabetic patients without thrombosis (early onset of occurring thrombosis) had low level of PT with highly significant difference (P. value = 0.000) when compared with diabetes plus thrombosis and control groups.
Conclusion: We concluded that the Sudanese diabetic patients had a procoagulant state that would result in thrombosis, so we advocated that diabetic patients, specifically type 2 to take delivery of anticoagulant therapy for as a minimum a quick time as a preventative degree to keep away from thrombus formation, specifically cardiovascular.
- Common coagulation tests
- thrombotic complication
How to Cite
Boutayeb A, Lamlili ME, Boutayeb W, Maamri A, Ziyyat A, Ramdani N. The rise of diabetes prevalence in the Arab region; 2012.
Zhao L, Huang P. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk. International Journal of Clinical and Experimental Medicine. 2013;6(8):632.
Ali SF, Ali OW. Mean Platelet Volume in Type II diabetes Mellitus, case control study–Gezira Central Sudan. Gezira Journal of Health Sciences. 2010; 6(2).
Erem C, Hacıhasanoğlu A, Çelik Ş, Ovalı E, Ersöz HÖ, Ukinç K, et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Medical Principles and Practice. 2005;14(1): 22-30.
Khalaf FA, Ibrahim HR, Bedair HM, Allam MM, Elshormilisy AA, Ali ST, et al. Plasminogen activator inhibitor-1 gene polymorphism as a risk factor for vascular complications in type 2 diabetes mellitus. Egyptian Journal of Medical Human Genetics. 2019;20(1).
Ahmed MH, Awadalla H, Elmadhoun WM, Osman M, Noor SK, Almobarak AO. Prevalence and risk factors for acute coronary syndrome among sudanese individuals with diabetes: a population-based study. Cardiology Research. 2017; 8(5):184.
Eltom MA, Mohamed AHB, Elrayah-Eliadarous H, Yassin K, Noor SK; Elmadhoun, WM, et al. Increasing prevalence of type 2 diabetes mellitus and impact of ethnicity in north Sudan. Diabetes Research and Clinical Practice. 2018;136:93-99.
Ahmed M, Almobarak A, Badi S, Elmadhoun W, Tahir H. The prevalence and risk factors of stroke among Sudanese individuals with diabetes: Cross-sectional survey. Brain Circulation. 2020; 6(1):26.
Elmadhoun WM, Noor SK, Ibrahim AAA, Bushara SO, Ahmed MH. Prevalence of diabetes mellitus and its risk factors in urban communities of north Sudan: Population‐based study. Journal of Diabetes. 2016;8(6):839-846.
Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematology/Oncology Clinics of North America. 2007;21(1):1-11.
Monroe DM, Hoffman M. What does it take to make the perfect clot? Arteriosclerosis, Thrombosis, and Vascular Biology. 2006; 26(1):41-48.
Weisel J, Litvinov R. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents). 2008;6(3):161-180.
Bain BJ, Bates I, Laffan MA. Dacie and Lewis Practical Haematology E-Book: Expert Consult: Online and Print, Elsevier Health Sciences; 2016.
Barrett KE, Barman SM, Brooks HL, Yuan JXJ. Ganong’s review of medical physiology, McGraw-Hill Education; 2019.
Abstract View: 126 times
PDF Download: 51 times